Endocrinol Metab.  2018 Jun;33(2):204-210. 10.3803/EnM.2018.33.2.204.

Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis

• Trimboli P
• Giovanella L

• KMID: 2420488
• DOI: http://doi.org/10.3803/EnM.2018.33.2.204

Abstract

BACKGROUND
Calcitonin measurement is pivotal in the management of medullary thyroid carcinoma (MTC), but several pitfalls can affect its reliability. Other potential markers have been proposed, and procalcitonin (ProCT) has been reported as promising. The present study was undertaken to summarize the published data and provide more robust estimates on the reliability of ProCT as marker in the management of patients with MTC.
METHODS
The systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The sources comprised studies published through May 2018. Original articles that reported series of MTC patients undergone ProCT during postoperative follow-up were searched. A random-effects model was used for statistical pooling of the data. The I 2 index was used to quantify the consistency among the studies. The Egger test evaluated the possible presence of significant publication bias. Quality assessment of the studies was performed according to Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2).
RESULTS
According to inclusion and exclusion criteria five papers, reporting 296 MTC patients undergone ProCT evaluation, were finally selected. The number of MTC with recurrence was 140. The pooled sensitivity of ProCT in detecting recurrence was 96% (95% confidence interval [CI], 92% to 99%), with neither heterogeneity (I 2=0%) nor publication bias (Egger test, 3.16; P=0.99). The pooled specificity was 96% (95% CI, 87% to 100%) with mild heterogeneity (I 2=66.6%), while Egger test was not calculable.
CONCLUSION
The present meta-analysis provides evidence that ProCT is reliable to manage MTC patients during their postoperative follow-up.

Keyword

Thyroid cancer, medullary; Calcitonin; Procalcitonin; Thyroid nodule

MeSH Terms

Calcitonin
Follow-Up Studies
Humans
Population Characteristics
Publication Bias
Recurrence
Sensitivity and Specificity
Thyroid Gland*
Thyroid Neoplasms*
Thyroid Nodule
Calcitonin

Figure

• 

  Fig. 1 Flow-chart of search and selection of papers. ProCT, procalcitonin; MTC, medullary thyroid carcinoma.

• 

  Fig. 2 Pooled sensitivity of procalcitonin in detecting REC MTC (random effect). REC, recurrent MTC; MTC, medullary thyroid carcinoma; CI, confidence interval.

• 

  Fig. 3 Pooled specificity of procalcitonin in identifying NED MTC (random effect). NED, no evidence of disease; MTC, medullary thyroid carcinoma; CI, confidence interval.

Reference

1. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25:567–610. PMID: 25810047.

2. Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf). 2015; 82:280–285. PMID: 25047365.

3. Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv Anat Pathol. 2014; 21:26–35. PMID: 24316908.

4. Trimboli P, Giovanella L, Crescenzi A, Romanelli F, Valabrega S, Spriano G, et al. Medullary thyroid cancer diagnosis: an appraisal. Head Neck. 2014; 36:1216–1223. PMID: 23955938.

5. Trimboli P, Giovanella L. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med. 2015; 53:1507–1514. PMID: 25781697.

6. Trimboli P, Seregni E, Treglia G, Alevizaki M, Giovanella L. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Endocr Relat Cancer. 2015; 22:R157–R164. PMID: 25934688.

7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6:e1000100. PMID: 19621070.

8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177–188. PMID: 3802833.

9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–560. PMID: 12958120.

10. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56:455–463. PMID: 10877304.

11. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155:529–536. PMID: 22007046.

12. Bihan H, Becker KL, Snider RH, Nylen E, Vittaz L, Lauret C, et al. Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid. 2003; 13:819–822. PMID: 14558925.

13. Bolko P, Manuszewska-Jopek E, Michalek K, Wasko R, Jaskula M, Sowinski J. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Arch Immunol Ther Exp (Warsz). 2003; 51:415–419. PMID: 14692663.

14. Algeciras-Schimnich A, Preissner CM, Theobald JP, Finseth MS, Grebe SK. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2009; 94:861–868. PMID: 19088163.

15. Kaczka K, Mikosinski S, Fendler W, Jalocha-Kaczka A, Pomorski L. Can procalcitonin be useful for medullary thyroid cancer? Endokrynol Pol. 2010; 61:430–436. PMID: 21049453.

16. Kaczka K, Mikosinski S, Fendler W, Celnik A, Pomorski L. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Adv Clin Exp Med. 2012; 21:169–178. PMID: 23214280.

17. Walter MA, Meier C, Radimerski T, Iten F, Kranzlin M, Muller-Brand J, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer. 2010; 116:31–40. PMID: 19890958.

18. Kratzsch J, Petzold A, Raue F, Reinhardt W, Brocker-Preuss M, Gorges R, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem. 2011; 57:467–474. PMID: 21159900.

19. Trimboli P, Lauretta R, Barnabei A, Valabrega S, Romanelli F, Giovanella L, et al. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. Int J Biol Markers. 2018; 33:156–160. PMID: 29707993.

20. Giovanella L, Imperiali M, Ferrari A, Palumbo A, Lippa L, Peretti A, et al. Thyroid volume influences serum calcitonin levels in a thyroid-healthy population: results of a 3-assay, 519 subjects study. Clin Chem Lab Med. 2012; 50:895–900. PMID: 22628334.

21. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004; 61:299–310. PMID: 15355445.

22. Niccoli P, Conte-Devolx B, Lejeune PJ, Carayon P, Henry JF, Roux F, et al. Hypercalcitoninemia in conditions other than medullary cancers of the thyroid. Ann Endocrinol (Paris). 1996; 57:15–21. PMID: 8734284.

23. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C, Henry JF. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg. 2002; 26:886–890. PMID: 12016469.

24. Silva OL, Broder LE, Doppman JL, Snider RH, Moore CF, Cohen MH, et al. Calcitonin as a marker for bronchogenic cancer: a prospective study. Cancer. 1979; 44:680–684. PMID: 476577.

25. Zaidi M, Moonga BS, Bevis PJ, Bascal ZA, Breimer LH. The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci. 1990; 28:109–174. PMID: 1963534.

26. Fugazzola L, Pinchera A, Luchetti F, Iacconi P, Miccoli P, Romei C, et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers. 1994; 9:21–24. PMID: 8051432.

27. Becker KL, Snider RH, Silva OL, Moore CF. Calcitonin heterogeneity in lung cancer and medullary thyroid cancer. Acta Endocrinol (Copenh). 1978; 89:89–99. PMID: 211777.

28. Goltzman D, Tischler AS. Characterization of the immunochemical forms of calcitonin released by a medullary thyroid carcinoma in tissue culture. J Clin Invest. 1978; 61:449–458. PMID: 621283.

29. Austin LA, Heath H 3rd. Calcitonin: physiology and pathophysiology. N Engl J Med. 1981; 304:269–278. PMID: 7003392.

30. Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab. 2014; 99:2986–2994. PMID: 24840813.

31. Giovanella L, Imperiali M, Piccardo A, Taborelli M, Verburg FA, Daurizio F, et al. Procalcitonin measurement to screen medullary thyroid carcinoma: a prospective evaluation in a series of 2,705 patients with thyroid nodules. Eur J Clin Invest. 2018; 48:e12934. PMID: 29635700.

32. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis. A journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004; 89:1512–1525. PMID: 15070906.

33. Novotny AR, Luppa P, Rosenberg R, Schneider H, Maak M, Bartels H, et al. Procalcitonin can be used for monitoring sepsis in patients with medullary thyroid carcinoma. Thyroid. 2009; 19:1287–1289. PMID: 19785521.